$ATRA

Atara Biotherapeutics, Inc.

CIK:0001604464|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Commercialization revenue	$ 630	$ 17,575	$ 1,146	$ 115,724
Costs and operating expenses:
Cost of commercialization revenue	191	554	315	20,993
Research and development expenses	1,345	7,310	1,509	34,743
General and administrative expenses	3,814	6,514	7,411	17,989
Total costs and operating expenses	5,350	14,378	9,235	73,725
Income (loss) from operations	(4,720)	3,197	(8,089)	41,999
Other income (expense), net:
Interest income	78	143	132	379
Interest expense	(191)	(972)	(1,021)	(1,989)
Other income (expense), net	0	22	0	11
Total other income (expense), net	(113)	(807)	(889)	(1,599)
Income (loss) before provision for (benefit from) income taxes	(4,833)	2,390	(8,978)	40,400
Provision for (benefit from) income taxes	1	3	1	3
Net income (loss)	(4,834)	2,387	(8,979)	40,397
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	(2)	0	(3)	(8)
Comprehensive income (loss)	$ (4,836)	$ 2,387	$ (8,982)	$ 40,389
Basic (loss) earnings per common share	$ (0.32)	$ 0.2	$ (0.62)	$ 3.52
Diluted (loss) earnings per common share	$ (0.32)	$ 0.19	$ (0.62)	$ 3.49
Basic weighted-average shares outstanding	15,033	12,197	14,560	11,484
Diluted weighted-average shares outstanding	15,033	12,310	14,560	11,576

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net income (loss)	$ (8,979)	$ 40,397
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation expense	1,143	7,010
Depreciation and amortization expense	43	2,031
Accretion of liability related to sale of future revenues	987	1,809
Amortization (accretion) of investment premiums (discounts)	(29)	258
Non-cash operating lease expense	376	4,413
Loss on impairment of lease right-of-use asset	0	4,130
Gain on derecognition of lease liabilities	0	(1,167)
Other non-cash items, net	100	547
Changes in operating assets and liabilities:
Accounts receivable	935	1,482
Inventories	0	10,655
Other current assets	(862)	6,211
Other assets	110	(4)
Accounts payable	697	(3,066)
Accrued compensation	(572)	(4,037)
Accrued research and development expenses	(25)	(7,013)
Other current liabilities	81	(1,438)
Deferred revenue	59	(93,485)
Operating lease liabilities	(496)	(4,190)
Other long-term liabilities	21	1
Net cash used in operating activities	(6,411)	(35,456)
Investing activities
Purchases of short-term investments	(6,626)	(5,419)
Proceeds from maturities and sales of short-term investments	0	17,199
Proceeds from sale of property and equipment	0	349
Net cash (used in) provided by investing activities	(6,626)	12,129
Financing activities
Proceeds from issuance of common stock through ATM facilities, net	7,776	0
Proceeds from sale of pre-funded warrants to purchase common stock in an underwritten registered direct offering or registered direct offering, net	0	15,304
Proceeds from employee stock awards	0	1
Principal payments on finance lease obligations	0	(250)
Other financing activities, net	0	(1)
Net cash provided by financing activities	7,776	15,054
Increase (decrease) in cash, cash equivalents and restricted cash	(5,261)	(8,273)
Cash, cash equivalents and restricted cash at beginning of period	8,482	25,176
Cash, cash equivalents and restricted cash at end of period	3,221	16,903
Non-cash financing activities
Issuance of pre-funded warrants in connection with HCRx Amendment	1,672	0
Accrued costs related to underwritten registered direct offering	0	461
Accrued costs related to ATM facility	103	0
Supplemental cash flow disclosure
Cash paid for interest	229	118
Cash paid for income taxes	$ 1	$ 3

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 3,221	$ 8,482
Short-term investments	6,652	0
Accounts receivable	318	1,253
Other current assets	3,339	2,477
Total current assets	13,530	12,212
Property and equipment, net	41	73
Operating lease assets	6,688	7,064
Other assets	765	886
Total assets	21,024	20,235
Current liabilities:
Accounts payable	824	127
Accrued compensation	699	1,271
Accrued research and development expenses	57	82
Deferred revenue	775	716
Liability related to the sale of future revenues - current portion	1,032	9,750
Other current liabilities	3,460	2,976
Total current liabilities	6,847	14,922
Operating lease liabilities - long-term	8,782	9,347
Liability related to the sale of future revenues - long-term	40,506	32,673
Other long-term liabilities	1,885	1,795
Total liabilities	58,020	58,737
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Common stock - $0.0001 par value, 500,000 shares authorized as of June 30, 2026 and December 31, 2025; 9,443 and 7,324 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	1,993,849	1,983,361
Accumulated other comprehensive income (loss)	(2)	1
Accumulated deficit	(2,030,844)	(2,021,865)
Total stockholders' equity (deficit)	(36,996)	(38,502)
Total liabilities and stockholders' equity (deficit)	$ 21,024	$ 20,235